Linfomi High dose sequential chemotherapy with autologous transplantation versus dose - dense chemotherapy MegaCEOP as first line treatment in poor - prognosis diffuse large cell lymphoma : an “ Intergruppo Italiano Linfomi ” randomized trial
نویسندگان
چکیده
Anna Marina Liberati Maria Giuseppina Cabras Massimo Federico Emanuele Angelucci Luca Baldini Carola Boccomini Maura Brugiatelli Roberta Calvi Giovannino Ciccone Angelo Genua Giorgio Lambertenghi Deliliers Alessandro Levis Guido Parvis Enzo Pavone Flavia Salvi Marco Sborgia Eugenio Gallo on behalf of the Intergruppo Italiano Linfomi High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial
منابع مشابه
Dose-dense and high-dose chemotherapy plus Rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma at poor prognosis: a phase II multicenter study
| 1 | haematologica | 2009; 94(9)
متن کاملNew proposal for the treatment of poor prognosis young patients with advanced stage diffuse large B-cell lymphoma Nova proposta de tratamento no linfoma difuso de grandes células B no paciente jovem de mau prognóstico em estágio avançado
Sergio Cortelazzo1 Patients with DLBCL now have a better outcome with a longer survival because of two major developments: 1) increasing the dose of active drugs with shortening the time between cycles, resulting in dose-dense or dose-intense regimens; and 2) combining rituximab with chemotherapy. Both strategies were associated with a better clinical outcome, particularly in patients without a...
متن کاملFour versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
BACKGROUND Patients with aggressive lymphoma and high-risk features at the time of diagnosis are reported to have a poor prognosis with standard therapy. Attempts to improve the results achieved with the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) using second-generation or third-generation chemotherapy have failed. In the current study, the authors increase...
متن کاملAutologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.
High-dose chemotherapy supported by autologous stem cell support/transplantation (HDT/ASCT) has been a standard of care over the last two decades in patients with relapsed or refractory(R/R) diffuse large B-cell lymphoma (DLBCL), which is sensitive to salvage chemotherapy. HDT/ASCT for high-risk DLBCL in upfront setting remains controversial, so it is not recommended for clinical practice. Vari...
متن کاملABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
BACKGROUND In 1997, the Intergruppo Italiano Linfomi started a randomized trial to evaluate, in unfavorable stage IA and IIA Hodgkin's lymphoma (HL) patients, the efficacy and toxicity of the low toxic epirubicin, vinblastine and etoposide (EVE) regimen followed by involved field radiotherapy in comparison to the gold standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimen f...
متن کامل